### Edgar Filing: BIENAIME JEAN JACQUES - Form 4

BIENAIM Form 4 March 06, 2	ЛЛ	STATES SEC					COMMISSIO		B APPROVAL 3235-0287	
Check t	this box		Washington	n, D.C. 2	0549			Numbe	r: January 31	
if no los subject Section Form 4	nger to <b>STATE</b> 16.	MENT OF CH	NERSHIP O	Estimat burden	2005 ed average hours per					
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Form 5 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940								Sc 0.3		
(Print or Type	e Responses)									
1. Name and Address of Reporting Person <u>*</u> BIENAIME JEAN JACQUES			2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL INC [BMRN]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) C/O BIOM PHARMA LINDARC	IARIN CEUTICAL INC	(Mor 03/0	<ul><li>3. Date of Earliest Transaction</li><li>(Month/Day/Year)</li><li>03/02/2018</li></ul>				_X_ Director 10% Owner _X_ Officer (give title Other (specify below) below) Chief Executive Officer			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
	AEL, CA 94901						Person		ie Reporting	
(City)	(State)	(Zip)	Table I - Non	-Derivativ	e Seci	irities Ac	quired, Disposed	of, or Benef	icially Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Yea	Code ur) (Instr. 8)	4. Securi on(A) or D (Instr. 3, Amount	ispose	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	03/02/2018	03/02/2018	М	1,000	А	\$ 14.39	273,216	D		
Common Stock	03/02/2018	03/02/2018	F	8,542	D	\$ 79.86	264,674	D		
Common Stock							182,201	I	Shares held by Jean-Jacques Bienaime Family Trust	

#### Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of 8 Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to buy Common Stock)	\$ 14.39	03/02/2018	03/02/2018	М	1,000	11/12/2009	05/11/2019	Common Stock	1,000

# **Reporting Owners**

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
BIENAIME JEAN JACQUES C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL, CA 94901	Х		Chief Executive Officer			
Signatures						
/s/ Laura Randall Woodhead, Attorney-in-Fact	03/0	6/2018				
**Signature of Reporting Person	D	ate				
Evolution of Dechanges						

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Reflects the number of options outstanding after the transactions from this specific stock option grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

### Edgar Filing: BIENAIME JEAN JACQUES - Form 4

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.